From GlobeNewswire:

SCYNEXIS, Inc. has announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference in Milan, Italy. The study showed SCY-247’s efficacy in treating Mucorales pulmonary infection in immunosuppressed mice and offers potential for treating devastating and often lethal fungal diseases such as mucormycosis.

According to the study led by Dr. Ashraf Ibrahim, SCY-247 demonstrated equivalent in vivo efficacy to currently used antifungals in treating a Mucorales pulmonary infection in mice. The combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement compared to monotherapy. SCYNEXIS views these results as very encouraging and intends to begin clinical studies for SCY-247 by the end of the year.

SCY-247 is a second generation antifungal compound from a novel class of structurally distinct glucan synthase inhibitors, triterpenoids, known as fungerps. It is currently in the pre-IND development stage and has demonstrated broad-spectrum antifungal activity in both in vitro and in vivo settings. SCYNEXIS anticipates seeking Qualified Infectious Disease Product (QIDP) and Fast Track designations for the FDA approval of SCY-247.

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines for difficult-to-treat and drug-resistant infections. The company’s proprietary antifungal platform, “fungerps,” has produced the first representative of its novel class. The company’s leading antifungal asset, Ibrexafungerp, has been licensed to GSK and is currently undergoing late-stage clinical investigation for the treatment of life-threatening invasive fungal infections in hospitalized patients.



Read more: SCYNEXIS to Present Preclinical Data on Second Generation